Merus Labs International Inc., a specialty pharmaceutical company, owns, markets, and distributes pharmaceutical products primarily in Europe and Canada. The company offers Elantan, Isoket, and Deponit nitrates for acute and chronic coronary artery disease; Sintrom for the treatment and prevention of thromboembolism diseases; Emselex/Enablex, for the treatment of overactive bladder syndrome; Surgestone and Provames for various health indications in women’s; Speciafoldine for macrocytic anemia; and Tredemine for tapeworm. It also provides Salagen for the treatment of symptoms of dry eye and dry mouth disorders, as well as for xerostomia following radiation therapy; Estraderm MX for the treatment of signs and symptoms of estrogen deficiency due to menopause, and for the prevention of accelerated postmenopausal bone loss; and Vancocin for the treatment of gastrointestinal tract bacterial infections. The company is headquartered in Toronto, Canada. As of July 17, 2017, Merus Labs International Inc. operates as a subsidiary of Norgine B.V.